Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.

Mäki-Petäjä KM.; McGeoch A.; Yang LL.; Hubsch A.; McEniery CM.; Meyer PAR.; Mir F.; Gajendragadkar P.; Ramenatte N.; Anandappa G.; Santos Franco S.; Bond SJ.; Schönlieb C-B.; Boink Y.; Brune C.; Wilkinson IB.; Jodrell DI.; Cheriyan J.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.

Mäki-Petäjä KM., McGeoch A., Yang LL., Hubsch A., McEniery CM., Meyer PAR., Mir F., Gajendragadkar P., Ramenatte N., Anandappa G., Santos Franco S., Bond SJ., Schönlieb C-B., Boink Y., Brune C., Wilkinson IB., Jodrell DI., Cheriyan J.

[Figure: see text].

Original publication

DOI

10.1161/HYPERTENSIONAHA.120.16454

Type

Journal article

Journal

Hypertension

Publication Date

05/05/2021

Volume

Pages

1591 - 1599

Keywords

acetylcholine, cardiovascular disease, hypertension, microvascular rarefaction, pazopanib, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Cardiac Output, Endothelium, Vascular, Female, Hemodynamics, Humans, Hypertension, Indazoles, Male, Middle Aged, Neoplasms, Pyrimidines, Receptors, Vascular Endothelial Growth Factor, Sulfonamides, Vascular Resistance, Vascular Stiffness